520 related articles for article (PubMed ID: 33666253)
21. A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19.
Hashemian SM; Farhadi T; Velayati AA
Drug Des Devel Ther; 2020; 14():3215-3222. PubMed ID: 32821086
[TBL] [Abstract][Full Text] [Related]
22. In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2.
Szemiel AM; Merits A; Orton RJ; MacLean OA; Pinto RM; Wickenhagen A; Lieber G; Turnbull ML; Wang S; Furnon W; Suarez NM; Mair D; da Silva Filipe A; Willett BJ; Wilson SJ; Patel AH; Thomson EC; Palmarini M; Kohl A; Stewart ME
PLoS Pathog; 2021 Sep; 17(9):e1009929. PubMed ID: 34534263
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture.
Bafna K; White K; Harish B; Rosales R; Ramelot TA; Acton TB; Moreno E; Kehrer T; Miorin L; Royer CA; García-Sastre A; Krug RM; Montelione GT
Cell Rep; 2021 May; 35(7):109133. PubMed ID: 33984267
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of SARS-CoV-2 polymerase by nucleotide analogs from a single-molecule perspective.
Seifert M; Bera SC; van Nies P; Kirchdoerfer RN; Shannon A; Le TT; Meng X; Xia H; Wood JM; Harris LD; Papini FS; Arnold JJ; Almo S; Grove TL; Shi PY; Xiang Y; Canard B; Depken M; Cameron CE; Dulin D
Elife; 2021 Oct; 10():. PubMed ID: 34617885
[TBL] [Abstract][Full Text] [Related]
25. Remdesivir and Ledipasvir among the FDA-Approved Antiviral Drugs Have Potential to Inhibit SARS-CoV-2 Replication.
Pirzada RH; Haseeb M; Batool M; Kim M; Choi S
Cells; 2021 Apr; 10(5):. PubMed ID: 33946869
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice.
Schäfer A; Martinez DR; Won JJ; Meganck RM; Moreira FR; Brown AJ; Gully KL; Zweigart MR; Conrad WS; May SR; Dong S; Kalla R; Chun K; Du Pont V; Babusis D; Tang J; Murakami E; Subramanian R; Barrett KT; Bleier BJ; Bannister R; Feng JY; Bilello JP; Cihlar T; Mackman RL; Montgomery SA; Baric RS; Sheahan TP
Sci Transl Med; 2022 May; 14(643):eabm3410. PubMed ID: 35315683
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and antiviral activity of fatty acyl conjugates of remdesivir against severe acute respiratory syndrome coronavirus 2 and Ebola virus.
El-Sayed NS; Jureka AS; Edwards MR; Lohan S; Williams CG; Keiser PT; Davey RA; Totonchy J; Tiwari RK; Basler CF; Parang K
Eur J Med Chem; 2021 Dec; 226():113862. PubMed ID: 34583312
[TBL] [Abstract][Full Text] [Related]
28. Remdesivir against COVID-19 and Other Viral Diseases.
Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
[TBL] [Abstract][Full Text] [Related]
29. Combined computational and cellular screening identifies synergistic inhibition of SARS-CoV-2 by lenvatinib and remdesivir.
Pohl MO; Busnadiego I; Marrafino F; Wiedmer L; Hunziker A; Fernbach S; Glas I; Moroz-Omori EV; Hale BG; Caflisch A; Stertz S
J Gen Virol; 2021 Jul; 102(7):. PubMed ID: 34319869
[TBL] [Abstract][Full Text] [Related]
30. Development and optimization of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity: Evaluation of 5676 Phase 1 Passed Structures.
Chiu W; Verschueren L; Van den Eynde C; Buyck C; De Meyer S; Jochmans D; Bojkova D; Ciesek S; Cinatl J; De Jonghe S; Leyssen P; Neyts J; Van Loock M; Van Damme E
J Med Virol; 2022 Jul; 94(7):3101-3111. PubMed ID: 35229317
[TBL] [Abstract][Full Text] [Related]
31. On the molecular structure of Remdesivir for the treatment of Covid-19.
Sheikholeslami SM; Jahanbani A; Shao Z
Comput Methods Biomech Biomed Engin; 2021 Jul; 24(9):995-1002. PubMed ID: 33356621
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine.
Plaze M; Attali D; Prot M; Petit AC; Blatzer M; Vinckier F; Levillayer L; Chiaravalli J; Perin-Dureau F; Cachia A; Friedlander G; Chrétien F; Simon-Loriere E; Gaillard R
Int J Antimicrob Agents; 2021 Mar; 57(3):106274. PubMed ID: 33387629
[TBL] [Abstract][Full Text] [Related]
33. Genome-scale metabolic modeling reveals SARS-CoV-2-induced metabolic changes and antiviral targets.
Cheng K; Martin-Sancho L; Pal LR; Pu Y; Riva L; Yin X; Sinha S; Nair NU; Chanda SK; Ruppin E
Mol Syst Biol; 2021 Nov; 17(11):e10260. PubMed ID: 34709707
[TBL] [Abstract][Full Text] [Related]
34. In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2.
Pizzorno A; Padey B; Dubois J; Julien T; Traversier A; Dulière V; Brun P; Lina B; Rosa-Calatrava M; Terrier O
Antiviral Res; 2020 Sep; 181():104878. PubMed ID: 32679055
[TBL] [Abstract][Full Text] [Related]
35. Off-Target
Xu Y; Barauskas O; Kim C; Babusis D; Murakami E; Kornyeyev D; Lee G; Stepan G; Perron M; Bannister R; Schultz BE; Sakowicz R; Porter D; Cihlar T; Feng JY
Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33229429
[TBL] [Abstract][Full Text] [Related]
36. Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs.
Schooley RT; Carlin AF; Beadle JR; Valiaeva N; Zhang XQ; Clark AE; McMillan RE; Leibel SL; McVicar RN; Xie J; Garretson AF; Smith VI; Murphy J; Hostetler KY
Antimicrob Agents Chemother; 2021 Sep; 65(10):e0115521. PubMed ID: 34310217
[TBL] [Abstract][Full Text] [Related]
37. Unlike Chloroquine, Mefloquine Inhibits SARS-CoV-2 Infection in Physiologically Relevant Cells.
Sacramento CQ; Fintelman-Rodrigues N; Dias SSG; Temerozo JR; Da Silva APD; da Silva CS; Blanco C; Ferreira AC; Mattos M; Soares VC; Pereira-Dutra F; Miranda MD; Barreto-Vieira DF; da Silva MAN; Santos SS; Torres M; Chaves OA; Rajoli RKR; Paccanaro A; Owen A; Bou-Habib DC; Bozza PT; Souza TML
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215969
[TBL] [Abstract][Full Text] [Related]
38. Antiviral Activity of Umifenovir In Vitro against a Broad Spectrum of Coronaviruses, Including the Novel SARS-CoV-2 Virus.
Leneva I; Kartashova N; Poromov A; Gracheva A; Korchevaya E; Glubokova E; Borisova O; Shtro A; Loginova S; Shchukina V; Khamitov R; Faizuloev E
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452529
[TBL] [Abstract][Full Text] [Related]
39. Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants.
Pitts J; Li J; Perry JK; Du Pont V; Riola N; Rodriguez L; Lu X; Kurhade C; Xie X; Camus G; Manhas S; Martin R; Shi PY; Cihlar T; Porter DP; Mo H; Maiorova E; Bilello JP
Antimicrob Agents Chemother; 2022 Jun; 66(6):e0022222. PubMed ID: 35532238
[TBL] [Abstract][Full Text] [Related]
40. Human soluble ACE2 improves the effect of remdesivir in SARS-CoV-2 infection.
Monteil V; Dyczynski M; Lauschke VM; Kwon H; Wirnsberger G; Youhanna S; Zhang H; Slutsky AS; Hurtado Del Pozo C; Horn M; Montserrat N; Penninger JM; Mirazimi A
EMBO Mol Med; 2021 Jan; 13(1):e13426. PubMed ID: 33179852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
